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Tumor Necrosis Factor-alpha (TNF-α), a multifunctional cytokine responsible for providing 
resistance against infections, inflammation, and cancers. TNF-α has emerged as a promising drug 
target against several autoimmune and inflammatory disorders. Several synthetic antibodies 
(Infliximab, Etanercept, and Adalimumab) are available, but their potential to cause severe side 
effects has prompted them to develop alternative small molecules-based therapies for inhibition 
of TNF-α. In the present study, combined in silico approaches based on pharmacophore modeling, 
virtual screening, molecular docking, and molecular dynamics studies were employed to 
understand significant direct interactions between TNF-α protein and small molecule inhibitors. 
Initially, four different small molecule libraries (~17.5 million molecules) were virtually screened 
against the selected pharmacophore model. The identified hits were further subjected to molecular 
docking studies. The three potent lead compounds (ZINC05848961, ZINC09402309, 
ZINC04502991) were further subjected to 100 ns molecular dynamic studies to examine their 
stability. Our docking and molecular dynamic analysis revealed that the selected lead compounds 
target the TNF receptor (TNFR) and efficiently block the production of TNF. Moreover, in silico 
ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) analysis revealed that all 
the predicted compounds have good pharmacokinetic properties with high gastrointestinal 
absorption and a decent bioavailability score. Furthermore, toxicity profiles further evidenced that 
these compounds have no risk of being mutagenic, tumorigenic, reproductive and irritant except 
ZINC11915498. In conclusion, the present study could serve as the starting point to develop new 
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TNF-α is an important proinflammatory cytokine responsible for several physiological and 
pathological conditions including Rheumatoid arthritis (McInnes, Buckley & Isaacs, 2015), 
Inflammatory bowel diseases (IBD) (Sticherling, 2016), Ankylosing spondylitis (Maxwell et al., 
2015), Psoriasis (Adegbola, Sahnan, Warusavitarne, Hart & Tozer, 2018) and gastric-carcinoma 
(Jang et al., 2009). It is chiefly produced by macrophages/ monocytes, mast cells, fibroblast, and 
natural killer cells during the acute phase reaction. TNF-α is involved in various signaling events 
inside the cells, leading to necrosis or apoptosis (Idriss & Naismith, 2000).  It exists in two 
biological forms; membrane-bound TNF (m-TNF) and secreted TNF(s-TNF) released after 
proteolytic cleavage of the membrane bound iso-form. s-TNF is present in blood plasma and 
circulate in the body to perform its endocrine function. Both forms of TNF-α (m-TNF & s-TNF) 
are biologically active having different functions (Wajant, Pfizenmaier & Scheurich, 2003, 
Palladino, Bahjat, Theodorakis & Moldawer, 2003). The signaling of TNF begins when TNF-α 
binds to its cognate receptors (TNFRs) such as TNFR1 (Tumor Necrosis Factor Receptor 1) and 
TNFR2 (Tumor Necrosis Factor Receptor 2) (Liang et al., 2013). TNFR1 is found in many types 
of cells, while TNFR2 is expressed only on the immune cells. The two receptor types; TNFR1 and 
TNFR2, tend to bind soluble and membrane-bound forms of TNF α, respectively (Chan, Siegel & 
Lenardo, 2000, Sedger & McDermott, 2014).  
TNF inhibition has been achieved by blocking TNF binding to its receptors to avoid the adverse 
effects (Papadakis & Targan, 2000). The pleiotropy of TNF validates it as a therapeutic target for 
the treatment of various autoimmune and inflammatory disorders. Some FDA approved synthetic 






Golimumab (Bongartz, Matteson & Orenstein, 2005, Jacobi, Mahler, Schuler & Hertl, 2006, 
Monaco, Nanchahal, Taylor & Feldmann, 2014) inhibits TNF-α directly and successfully used for 
the treatment of some inflammatory diseases including Crohn’s disease, Rheumatoid arthritis and 
Ulcerative colitis (Mesaik et al., 2012). However, these therapeutic biologics have several side 
effects including the weakening of body defensive system by eliciting antigen-antibody response 
against self-antigens, high cost and painful administration (Hochberg, Lebwohl, Plevy, Hobbs & 
Yocum, 2005, Sfikakis & Tsokos, 2011, Lis, Kuzawińska & Bałkowiec-Iskra, 2014). The dilemma 
has made researchers pay more attention towards designing small molecule inhibitors against 
TNF-α. Currently, small molecule-based therapies are the most promising alternative approach to 
develop potent TNF-α inhibitors because they are low cost, easy to manufacture and deliver to the 
target tissue (Davis & Colangelo, 2013). Unfortunately, very few small-molecule inhibitors are 
available, but none of them has reached clinical trials. It is very challenging to find a low molecular 
weight compound that interacts directly with protein to block its function (Buchwald, 2010). To 
date, most small molecules interact with TNF-α indirectly by downregulating its expression and 
some inhibitors promote direct disassembly of TNF-α with its receptors (Berg, 2003). Suramin and 
SPD307 promote disassembly of TNF with its receptor by disrupting the binding of TNF-α trimer 
complex but not considered as potent TNF inhibitors due to their low potency and toxicity 
(Mancini et al., 1999, He, 2005).  
Even after such extensive work, due to lower potency and higher cytotoxicity profiles of small 
molecular inhibitors researchers still target TNF-α to find more potent inhibitors to reduce the 
higher cost and side effects of currently available treatments. Therefore, in the present study, we 
used ligand-based pharmacophore modeling, virtual screening, molecular docking studies to 






of selected hits to gain insight into the real dynamic behavior and binding mechanism of TNF-
alpha with its inhibitors. Moreover, pharmacokinetic and drug-likeness properties of selected hits 
were also determined to evaluate their potential to act as a drug candidate for TNF-α. 
 
2. Material and methods 
2.1 Data set 
A set of 27 TNF-α inhibitors was collected from literature based on their experimental inhibitory 
activity (IC50 values) ranging from 0.004 μM to 60 μM (Fujita, 2002, Cheng & et al., 2004, 
Laufersweiler & et al., 2004, Sabat & et al., 2006,  Dhuru et al., 2011, Mouchlis, et al., 2012, Shah 
et al., 2012, Guirado et al., 2013, Kim et al., 2014). The 3D structure of these compounds was 
sketched by using ChemDraw Ultra 11.0 software (Li et al., 2004) followed by atom typing 
correction and geometry optimization by Sybyl Tripos 7.3. (SYBYL7.3, 2007). Energy 
minimization of the dataset was performed by the Tripos molecular mechanics force field through 
Powell's conjugate gradient method (Clark, Cramer, and Van Opdenbosch, 1989) with one 
thousand steps and 0.5 kcal/mol Å threshold. To calculate partial atomic charges Gasteiger-Huckel 
charges (Gasteiger, 2005) were applied to all the ligands by AutoDock 4.2 software (Morris et al., 
2009) and hydrogen atoms were added to the whole dataset. These 27 reported inhibitors belong 
to the diverse classes of inhibitors and they were used for the ligand-based pharmacophore 























2.2 Receptor preparation 
To get initial coordinates of TNF-α, the crystal structure of human tumor necrosis factor-alpha 
with reported inhibitor (307) measured at 2.1 resolution was downloaded from RCSB Protein Data 
Bank under the accession code 2AZ5 (Berman, 2000, He, 2005). TNF-α is a homotrimer, 
containing three chains (A, B, C) but chain C was removed due to its similarity with chains A and 
B (Tang, Hung & Klostergaard, 1996). Therefore, chains A and B were selected because the 







started from the modeling of missing residues via Modeller9.23 software (Šali & Blundell, 1993) 
and the quality of model was assessed using PROCHECK (Laskowski, MacArthur, Moss & 
Thornton, 1993), ERRAT (Colovos & Yeates, 1993) and Verify3D (Bowie, Luthy & Eisenberg, 
1991, Lüthy, Bowie & Eisenberg, 1992) online servers, followed the addition of missing bonds 
and atoms, removal of heteroatoms, and water molecules using the protein preparation module in 
MOE2019.01 software (Vilar et al., 2008). Further Hydrogen atomes were added by using the 
protonate 3D algorithm, while partial charges were assigned via AMBER99 Force Field 
implemented in MOE2019.01. 
 
 







2.3 Ligand-Based pharmacophore modelling 
In our study, a single crystallized complex structure (PDB ID: 2AZ5) was available. As a 
compensation, we employed the coordinates of the ligand protein complexes, obtained after 
docking the reported inhibitors with PDB: 2AZ5, to generate structure-based pharmacophore 
models. However, the models failed to produce significant features for pharmacophore generation. 
Therefore, ligand-based pharmacophore modeling has been implemented in this study. All the 
ligand-based pharmacophore modeling studies were performed using Ligandscout4.2 (Wolber & 
Langer, 2005). The ligand-based approach requires the active conformation of reported inhibitors 
to develop a model. In this study, information extracted from 27 reported TNF inhibitors was used 
to create pharmacophores, which were used in different combinations for modeling 
pharmacophores with either merged or shared features, or combination of both. The generated 
models were further with the help of active, decoys and random datasets of compounds.  
 
2.4 Validation of Generated Pharmacophore Model 
The developed pharmacophores were analyzed to validate their ability to extract active molecules 
from a large data set of unknown molecules. In the present study, three datasets such as actives, 
random, and decoys were used for the validation of constructed pharmacophore model. The test 
set of active compounds contained 27 reported TNF-α inhibitors retrieved from the literature based 
on their good inhibitory activity (0.004μM to 0.323μM) (Table 1). The random dataset comprised 
80 compounds (Table S2) that were collected randomly from various commercial databases and 
have not been tested against TNF protein. The third dataset was created by using DUDE (Directory 
of useful decoys enhanced) web server (Mysinger, Carchia, Irwin & Shoichet, 2012). The DUDE 






validation of our generated pharmacophore model. Twenty-seven active compounds were 
submitted in smile format to this web server that generated 50 decoys for every compound, hence 
it provided us with a total of 1350 compounds that have similar physical and chemical properties 
to the active compounds illustrated in (Table S3). All the datasets (test, decoys, and random) were 
converted from mol2 to ldb (ligands out database) format with the help of the idbgen module of 
LigandScout4.2 software. These datasets were then ready to use for the validation process of our 
generated pharmacophore models. This validation protocol is important because it ensures that our 
generated model is reliable, and it can detect the known active molecules correctly from the large 
data of unknown molecules.  
      
2.5 Virtual screening 
The main goal of screening the virtual database is to find those potential lead compounds which 
slightly vary in their chemical structure but with strong inhibitory activity against the target 
receptor. All the dataset of screening compounds was downloaded from 4 commercially available 
compounds libraries including Chembridge (Eugene et al., 2010) (~50,000 compounds), 
Maybridge (ScrGuide, 2004) (~10,6,478 compounds), NCI (Stinson et al., 1992)  
(~2,65,242compounds) and ZINC (Irwin and Shoichet, 2005)  (~17,000000 compounds). Initially, 
~17.5 million compounds from all the four databases were checked for their drug-likeness 
properties by using the Lipinski rules (Lipinski, 2004). Moreover, obtained hits were passed 
through the second filter based on their similarity (2D features) with the reported TNF-α inhibitors 
(Table S1). Furthermore, these compounds were subjected to the third filter by using the Tanimoto 
coefficient (Willett, Barnard & Downs, 1998) analysis. In Tanimoto coefficient analysis many 






takes place and it assigns the similarity index (ranges 0-1) to the test compound which shows 
similarity with the query compound. After creating a virtual database, it has been converted into 
the Tripos multimol2 files and subjected to the minimization step to achieved most stable and 
lowest energy conformation by using omega module of OpenEye software (OpenEye scientific 
software), then gasteiger charges were applied, and hydrogens were added to all compounds. 
Finally, the ligand dataset is prepared for the assessment of the docking procedure against the 
selected TNF protein. 
 
2.6 Statistical Analysis (Enrichment factor (EF) & ROC curve) 
The virtual screening results were evaluated by their enrichment factor (Bender & Glen, 2005) and 
Receiver operating curve analysis (Truchon & Bayly, 2007, Triballeau, Acher, Brabet, Pin & 
Bertrand, 2005). Enrichment factor is defined as the concentration of active compounds in a set of 
virtual screening results for assessment. It can be calculated by the following formula: 
Enrichment Factor =   Actives (in subset) / Actives (in total dataset)                                                         
No. of compounds( subset) / No. of compounds (in the total dataset) 
ROC curve is another powerful method that provides accuracy of virtual screening result’s and it 
has the potency to differentiate actives from the in-actives and create a boundary between them 
(Empereur-mot et al., 2015). It is created by plotting the true positive rate against the false-positive 
rate at several threshold settings. The area under the curve (AUC) is used to access the performance 










2.7 Molecular Docking 
Molecular docking simulation was performed using Auto Dock 4.2 (Morris et al., 2009) software 
due to its reproducible results in our redocking experiment (RMSD 1.3 Å). It is an automated 
docking software including a rigid receptor along with its flexible side chains and ligands that 
results in the best ligand binding pose with minimal binding energy (Morris et al., 2009). Auto 
Dock needs a pre-calculated grid map of each ligand atom and this grid must surround the active 
site of the protein. Koll man’s charges (Singh & Kollman, 1984) were applied to protein and 
Gasteiger charges (Gasteiger, 2005)   were applied to the ligands due to their non-peptide nature. 
Auto grid 4.2 (Morris et al., 2009) was used to create a grid box of 38 Å x 36 Å x 38 Å around the 
protein, it provides a rigid body cavity during docking simulations. The Lamarckian genetic 
algorithm (Fuhrmann, Rurainski, Lenhof & Neumann, 2010) was used to search for the best-fit 
ligand conformers. The grid spacing of 0.375 Å was suitable for docking and 1000000 times 
energy evaluation was performed for every ligand. Ten conformers were generated for every 
ligand and best-ranked ligand binding poses were selected for further evaluation. 
 
2.8 Re-docking 
Re-docking experiments were performed to check the software’s ability to reproduce the crystal 
pose of the cognate ligand. For this purpose, the performance of five software packages (Auto 
Dock4.2, MOE2019.1, GOLD, FRED and Surflex Dock.) were evaluated based on root mean 
square deviation (RMSD). RMSD serves as a gold standard to evaluate the reliability of the 
docking protocol (Ajmal Shah, Khalil, Ul-Haq & Panichayupakaranant, 2017). For a reliable 






crystal binding pose must be less than 3 Å. The ligand and receptor were prepared for re-docking 
experiments according to the software’s requirement. 
 
2.9 Molecular Dynamic (MD) Simulation 
To explore the structural and dynamic behavior in protein-ligand complexes 100 nano-second MD 
simulation was performed by utilizing the top three virtual hits and reference compounds as initial 
structures. Gromacs 5.1.4 software package (Abraham et al., 2015) was used to performed MD 
simulation. pdb2gmx tool was used to generate the coordinate topological file for target protein 
using the “GROMOS96 54a7” force field (Scott et al., 1999). The ligands topological files were 
generated by the ATB server (Malde et al., 2011) it converts coordinates of small molecules into 
pdb format. Each system was solvated in a cubic box with the protein placed at 10 Å distance from 
the box wall and SPC216 (Mark & Nilsson, 2001) (simple point charge) solvent model was used 
within the periodic boundary condition (PBC). All the systems were neutralized by the addition of 
counterions followed by the energy minimization of all the complexes in 50,000 steps to get rid of 
steric clashes. After the minimization step, all the systems were equilibrated to 300 K temperature 
for 100ps under NVT condition (constant temperature and volume) which further followed by NPT 
i.e. (temperature 300K and 1.0 atmospheric pressure) ensemble for 100ps along with periodic 
boundary condition. The temperature and pressure were coupled to the Berendsen thermostat and 
barostat (Berendsen, Postma, van Gunsteren, DiNola & Haak, 1984) with a coupling time of 0.1 
ps. The LINCS algorithm (Hess, Bekker, Berendsen & Fraaije, 1997) was used to fix the bond 
lengths and Coulomb and Vander Waals interactions were treated with a single cut off 10Å. 
Particle Mesh Ewald (PME) (Darden, York & Pedersen, 1993, Essmann et al., 1995) was used for 






and snaps shots were generated after every 2 femtoseconds to observe the real-time dynamics and 
stability of each complex. The results of MD Simulations were examined by using different 
modules of Gromacs software and graphs were plotted via the XMGrace tool. 
 
2.10 In silico Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) 
prediction 
To predict the pharmacokinetics and drug-likeness properties of selected hits compounds were 
submitted in the canonical smiles format to the SwissADME online server (Daina, Michielin & 
Zoete, 2017). This analysis was performed to predict the pharmacokinetic properties of hits such 
as Gastrointestinal absorption, P-glycoprotein (p-gp), Blood-brain Barrier permeability and 
inhibition of Cytochrome P450 isoforms. Moreover, drug-likeness and bioavailability score 
prediction was also conducted according to Lipinski (Lipinski, Lombardo, Dominy & Feeney, 
2001), Ghose (Ghose, Viswanadhan & Wendoloski, 1999), Veber (Veber et al., 2002), Egan 
(Egan, Merz, & Baldwin, 2000), Muegee (Muegge, 2003) rules. The drug-likeness rules by 
Lipinski, Ghose, and Weber were applied to predict drug-likeness of the molecules based on some 
important parameters such as MW (Molecular Weight), Slogp, logS and number of HBD and 
HBA. Egan rules provide a prediction of drug absorption properties based on the membrane 
permeability, while Muegee rules provide a prediction of pharmacophore points that differentiate 
between drug-like and non-drug-like molecules. The SwissADME online server utilizes a support 
vector machine algorithm (Cortes & Vapnik, 1995) with large datasets of known and non-
inhibitors along with substrates and non-substrates. The Toxicity profiles of hits compounds were 








3. Results and discussion 
Successful hits to lead optimization campaigns discovered few potent TNF-α inhibitors. For 
example, Chan et al identified two potent molecules (quinuclidine 1 and indoloquinolizidine 2) by 
ligand-based virtual screening and their experimental findings suggested that quinuclidine 1 has 
better efficacy than indoloquinolizidine 2 with the inhibitory concentration of 5µM and more 
compared to 30µM, respectively (Chan et al., 2010). Chio et al identified a potent compound 
(Oxole-1) using structure-based virtual screening that showed good inhibition of TNF at 10µm. 
(Choi, Lee, Park & Oh, 2010). A novel metal-based TNF inhibitor was also reported by Leung et 
al (Leung et al., 2012). Mouhsine et al. used combined in silico and in vitro screening methods to 
discover orally available TNF inhibitors (Mouhsine et al., 2017). Liang et. al, performed screening 
of bi-cyclic peptides libraries for protein-protein interaction inhibitors which lead to the discovery 
of TNF-α antagonist (Liang et al., 2013). Other works were also reported to discover TNF-α 
inhibitors. (Leung et al., 2011; Hanumanthappa et al, 2012; Mouchlis et al, 2012; Ma et al., 2014; 
Alexiou et al., 2014; Kang et al., 2016). Despite these efforts, the search for TNF-inhibitors is 
taking ground in drug discovery campaigns. For this reason, our ligand-based virtual screening 
campaign was designed to explore the vital interactions between TNF and its receptors that further 
used to develop novel and potent TNF-inhibitors. 
 
3.1 Protein Modelling 
Modeling of missing residues of TNF-α protein was performed via Modeller9.23 software (Šali & 






(PDB ID: 2AZ5) as in chain A, 16 residues were missing: Arg31, Arg32, Ala33, Asp34, Ala35, 
Gln102, Arg103, Glu104, Thr105, Pro106, Glu107, Gly108, Ala109, Glu110, Ala111, and 
Lys112. In chain B, 8 residues were missing Glu104, Thr105, Pro106, Glu107, Gly108, Ala109, 
Glu110, and Ala111. After modeling the residues PROCHECK was run to check the 
stereochemical quality of the modelled protein structure and Ramachandran plot (Ramachandran, 
Ramakrishnan & Sasisekharan, 1963) was obtained.  Ramachandran plot provides information on 
torsional or dihedral angles (phi and psi) of amino acid residues in protein structure. It consists of 
allowed and disallowed regions. The allowed region is low energy regions that are sterically 
favorable while the disallowed region is sterically unfavorable regions. The Ramachandran plot of 
our modeled structure shows 98.9% of residues were lying in favorable and allowed region only 
1.2% (3 residues) in the disallowed region indicating the reliability of the modeled structure as 
depicted in Figure 3. 
 
 
Figure 2. a) Unmodeled Structure of TNF protein. b) Modeled Structure of TNF protein. c) Alignment of modeled 









Figure 3. Ramachandran plot of modeled TNF-α protein showing the correlation of phi (Φ) and psi (Ψ) angles. The 
most favorable regions are shown in red color, additionally allowed, generously allowed and disallowed regions are 
shown in brown, yellow and light-yellow color respectively. 
 
3.1.1 ERRAT model validation 
ERRAT is an online server used to examine non-bonding interactions between atom pairs in the 
modelled protein’s structure. The overall ERRAT quality factor score was 85.606 depicted in 










Figure 4. Validation of modelled protein structure via ERRAT tool showing good ERRAT quality factor score. 
 
3.1.2 Verify3D model validation 
Verify3D analyzes protein structures based on their three-dimensional profiles. It examines the 
correlation of protein models (3D) and sequences of amino acids in 1-dimensional manner and 
assigns different structural classes to every residue according to their local environment. The 
Verify3D plot of our modelled structure shows that 80.7% residues have scored >= 0.2 in the 













Figure 5. Verify3D analysis of Modelled protein structure showing average 3D-1D score of all residues >= 0.2 
which is acceptable for modelled protein structure. 
 
3.2 Ligand-based Pharmacophore Generation 
Pharmacophore is defined as a molecular architecture that contains important features necessary 
for the biological activity of the drug (Gao, Yang & Zhu, 2010). In the current study, ligand-based 
pharmacophore modeling was used to generate a reliable pharmacophore model using 
LigandScout 4.2. For this purpose, 27 experimentally reported compounds that had good inhibitory 
activity against TNF-α were used to generate several shared or merge ligand-based 
pharmacophoric models. These generated pharmacophore models were used for virtual screening 
which leads to the identification of novel and potent lead compounds. In order to generate the 
model, ligands were aligned, and common features were extracted to find out the good 
pharmacophore model. Therefore, twelve pharmacophores models were generated by the 






features from experimentally reported inhibitors. The selection of these compounds based on their 
potency and structural diversity. The selected pharmacophore is derived from three potent 
inhibitors such as Compound 5 (IC50 0.004 μM), Compound 6 (IC50 0.004 μM) and compound 11 
(IC50 2 μM). Compounds 5 and 11 were presented with sixteen pharmacophoric features including 
four aromatic rings, six HBA (hydrogen bond acceptors), six hydrophobic and one HBD (hydrogen 
bond donor). Similarly, compounds 6 contained thirteen pharmacophoric features such as six 
HBA, four hydrophobic and three aromatic ring features as shown in Figure 6. Six HBA, three 
hydrophobic and three aromatic rings are found to be common in all three ligand-based 
pharmacophore models generated by these ligands. However, one HBD feature is restricted only 
for compounds 5 and 11.  
 
 
Figure 6. Pharmacophore representations of compound 11 (a) compound 5 (b) and Compound 6 (c) Pharmacophore 
models generated by LigandScout4.2. Green and red arrows represent H-bond donors and H-bond acceptors and 








Table 2 summarizes the generated pharmacophore models with their statistical parameters. All the 
generated models comprise of either four or five pharmacophore features (HBA, HBD, Hyd, Ar); 
all the models were varying in their composition, orientation, and vector directions. The 
combination of compounds used for the construction of pharmacophore models are shown in 
Table 2 and here we discussed only the selected pharmacophore model. Model 7 considered as 
the best pharmacophore model consists of two HBA, one hydrophobic and one aromatic feature 
as shown in Figure 7. These features were common among all the three active compounds and 
were necessary for inhibiting TNF-α at the nanomolar level. All the generated pharmacophore 
models were ranked based on the pharmacophore fit score, a default scoring function implemented 
in LigandScout software. This scoring function measures the best geometric fit of the features of 
a compound to the three-dimensional ligand-based pharmacophore model. A high pharmacophore 
fit score indicates the best fit for the model and those compounds that nicely fit the pharmacophore 
model should also show good activity at TNF-α. In our case, the pharmacophore fit score of all the 
virtual hits was higher (48.08-46.25) indicating that their chemical feature best aligned to the 
















Figure 7. Alignment of selected pharmacophore model 7 with compound 11 (a) compound 5 (b) and Compound 6 
(c) Pharmacophore models generated by LigandScout4.1. Green and red arrows represent H-bond donors and H-
bond acceptors and Yellow spheres represent hydrophobic areas; Blue sphere represents aromatic ring feature 
respectively. 
 
1.2 Validation of Generated Pharmacophore Model 
Prediction of active, inactive, random and decoys data set, was the initial step in the validation of 
the constructed pharmacophore model. The developed pharmacophore models were utilized for 
the estimation of hit rates of test datasets. Model 7 showed good hit rates other than developed 
models. The best pharmacophore model and its hits rates against active, inactive, random and 






aromatic and two HBA features. The selected pharmacophore showed 80% active identifying hit 
rate. In general, it predicted 22 highly active compounds out of 27 correctly indicating that this 
pharmacophore could pick compounds with high experimental activity against TNF-α. Moreover, 
the best pharmacophore model was further evaluated by decoys, inactive and random datasets. 9 
% decoys (125 out of 1350), 25% inactive (1 out of 4) and 2 % (2 from 80 compounds) random 
compounds were picked by the selected model 7 showing its good predictive ability to discriminate 
between active, inactive and decoys dataset. The pharmacophore models having a low picking rate 
of active compounds were not discussed here. The pharmacophore model (1, 3, 5 and 9) also 
showed higher picking rate of actives but they also picked decoys and inactive compounds in 
higher percentages and they cannot be considered as a good pharmacophoric model. 
 


































2 2, 3, 13 Model 2 Hyd, Ar, Ar, Ar, HBA, HBA 10 0 5 0 
3 9, 15 Model 3 Hyd, hyd, HBA, HBA 66 75 8 39 
4 8, 9 Model 4 Hyd, Hyd, HBA, HBA, HBA, 
HBD 
54 25 5 0 
5 24, 27 Model 5 Hyd, Hyd, Hyd, HBA 60 50 7 31 
6 4,13 Model 6 Hyd, Hyd, HBA, HBD 20 0 13 30 
7 5, 6, 11 Model 7 Hyd, Ar, HBA, HBA 80 25 2 9 
8 4, 5 Model 8 Hyd, Hyd, Hyd Ar, HBA, HBA, 
HBA, HBA, HBD 
7 0 3 0 
9 15, 20 Model 9 Hyd, HBA, HBA, HBA 83 50 15 36 
10 16, 22 Model 10 Hyd, Hyd, HBA, HBA, HBA, 
HBA 
23 0 3 6 
11 6, 23 Model 11 Hyd, Hyd, HBD, HBA, HBA 43 50 0 8 










1.2 Virtual Screening 
Virtual screening (VS) is an effective method, used for finding novel and potent active molecules 
(i.e. hits) as starting points for medicinal chemistry (Lavecchia & Giovanni, 2013). In our study, 
sequential filtration was performed prior to virtual screening. In order to find out the druggability 
of ~17 million compounds (compounds from all four databases; Chembridge, Maybridge, NCI and 
ZINC) all compounds were filtered as per Lipinski's rules. This rule states that molecules which 
possess drug-like properties must contain molecular weight ˂ 500, log P ˂ 5, hydrogen bond 
acceptor ˂ 5 and hydrogen bond donor ˂ 10 otherwise these molecules have poor absorption or 
permeation (Lipinski, 2004).  After Lipinski filtration, 12 million compounds were retrieved and 
subjected to active descriptors-based filtering. For this purpose, 2D descriptors of experimentally 
reported inhibitors such as MW (365-500 a.m.u), topological polar surface area (36-123), HBD 
(0-3), HBA (1-7), Slog P (2-7), formal charge (0-1) and number of rotatable bonds (2-11) were 
calculated by MOE2019.01 software (Table S1). The descriptor-based filtration provided 5 
million compounds which were further subjected to pharmacophore-based virtual screening. The 
validated pharmacophore model was used for this screening and yielded 42,000 hits. Moreover, 
these hits were evaluated for statistical analysis via calculation of the Enrichment Factor (EF) and 
ROC (AUC) curve. 
 
1.2 Statistical Analysis (Enrichment factor and ROC CURVE) 
The receiver operating curve is defined as a graphical plot of rate of true positives (sensitivity) 
versus the rate of false-positive (1-specificity) (Empereur-mot et al., 2015) as shown in Figure 8, 






both the information related to active and inactive and independent on the number of actives. The 
Area under curve (AUC) value of the best pharmacophore model is 0.67 indicating the reliability 
of the generated pharmacophore model. 
Enrichment factor (EF) is another statistical method commonly used for the assessment of virtual 
screening results (Bender & Glen, 2005). The efficiency of docking and scoring function can also 
be estimated through the calculation of enrichment factors at a different percentage of databases. 
EF used to access the discriminatory power of the constructed pharmacophore model to rank 
known active ligands in the top of the list. In this study, according to EF calculation, most of the 
known actives lie in 50 % of the database which contained approx. 21,000 hits that were further 
evaluated for the Tanimoto coefficient analysis. 
 
 
Figure 8. Receiver Operating Curve (ROC), a graphical plot between sensitivity (rate of true positive) versus 1-










1.2 Tanimoto Coefficient Analysis  
The 21,000 hits obtained after statistical analysis (EF and ROC Curve) were subjected to Similarity 
index calculation.  The most potent inhibitors (Compound 5, 6, 11) which were previously used in 
the generation of pharmacophore models were used as a query molecule for Tanimoto similarity 
searching at different cuts off range 0.6-0.8. Initially, several conformations against the query 
compounds were generated then shape-based overlapping takes place with respect to the query 
compound. Subsequently, 0.6-0.8 cut off was set to filter the obtained hits (21,000) and finally, 
4000 compounds were present in the predefined cut off the range. These 4000 compounds were 
further evaluated by molecular docking studies. 
 
1.3 Molecular Docking  
Molecular docking studies were performed to explore the binding modes of screened virtual hits. 
To evaluate the accuracy of docking software’s redocking experiments were performed. The 
redocking results revealed that the top-ranked poses predicted by Auto Dock 4.2 were like the 
crystal binding pose of reference ligand. The root means square deviation (RMSD) of regenerated 
crystal pose by AutoDock was 1.3 Å indicating the reliability of our docking protocol. Re-docked 
results were summarized in Table 3 and Figure 9. Therefore, AutoDock 4.2 was used for 
predicting the binding mode of shortlisted virtual hits and PDB ID: 2AZ5 was used as a molecular 
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1.3Å 
2 GOLD 11.9Å 
3 MOE-Dock 9.6Å 
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Figure 9.  The redocked pose of 307 (bound inhibitor of TNF-α PDB I.D: 2AZ5). The magenta color shows the 
extracted pose of SPD307 while cyan is the best re-docking posed obtained by Auto Dock 4.2. 
 
A total of 4,000 compounds were docked into the binding pocket of TNF-α protein. Top-ranked 
480 compounds were selected based on their good docking score and further subjected to visual 
inspection. All the compounds were then analyzed visually for interactions and their binding 






analysis 48 virtual hits showed good binding interaction with the hotspot residues of TNF-α. All 
the selected compounds belonged to the ZINC database. The criteria for selecting the most 
promising leads were based on their good pharmacophore fit score, dock score and strong binding 
interaction with the hotspot residues of TNF-α protein. Out of 48 hits, only 6 compounds were 
fulfilling the above-mentioned criteria and considered as promising leads compounds (Table 4). 
The pharmacophore mapping, docking score and visual inspection of these predicted lead 
candidates showed that they might act as novel and potent inhibitors of TNF-α. 
 













































































































The visual analysis showed that the all the selected leads showing significant binding pattern with 
the crucial active site residues of TNF-α such as the top-ranked pose of compound 1 with high 
dock score -8.45 kcal/mol  (ZINC058418961) showed that it stabilizes itself by mediating two 
strong hydrogen bonds with oxygen atom of Gly121A and another hydrogen bond with the amide 
nitrogen of Leu120A respectively. Compound 1 further stabilizes in the TNF binding pocket by 
showing some hydrophobic interaction with Leu57A, Leu57B, Tyr59A, Tyr59B and Gln61 of 
chain A. Quinoline ring of compound 1 showing pie-stacking interaction with the benzene ring of 
Tyr59 of chain B. Therefore, compound 1 accommodating itself with the simultaneous 
establishment of hydrogen bonds and hydrophobic interactions with hot spot residues proving its 
ability to inhibit TNF-α. 
The active site of TNF-α consists of many tyrosine residues and compound 2 (dock score -7.50 
kcal/mol) (ZINC09402309) established itself by interacting with these tyrosine residues. The top-
ranked pose of this compound showed several hydrophobic interactions with tyrosine residues of 
both chains A and B; Tyr59, Tyr119, and Tyr151 respectively. Additionally, compound 2 also 
involved in hydrophobic interaction with Leu57 and Gln61 of chain B. Moreover, this compound 
exhibit two hydrogen bonds with amide nitrogen and the oxygen atom of Gly121 of chain A. 
Furthermore, the hydroxyl group of the Tyr151A is involved in hydrophobic as well as hydrogen 
bonding interaction.  
Compound 3 (ZINC04502991) has shown good dock score (-7.45 kcal/mol) and resided in the 






contacts. As the binding site of TNF-α is largely hydrophobic due to the presence of many tyrosine 
residues such as Tyr59, Tyr119 and Tyr 151. These tyrosine residues of both the chains are 
involved in hydrophobic interaction with the ligand molecule. Besides these interactions, this 
compound stabilizes itself inside the binding pocket by mediating four hydrogen-bonding 
interactions with Ser60A, Gln61B, Tyr119A, and Leu120A. The two hydrogen bonds were 
observed between the oxygen atom of the ligand molecule that is attached to Sulphur and with the 
backbone amide nitrogen of Ser60A and Leu120A. Thiadiazol ring of ligand molecule mediates 
two hydrogen bonds in bidentate fashion with the carbonyl group of Tyr119A and with the 
backbone amide nitrogen of Gln61 of chain B. The strong hydrogen bonding with crucial residues 
provides stability to the protein and makes this compound as a strong lead candidate to inhibit 
TNF-α.  
Another lead compound 4 (ZINC29558932) with docks core of -7.10 kcal/mol mainly interacts 
with the protein’s binding site by hydrophobic interaction. Benzene ring of ligand molecules 
showed intermolecular interaction with the methyl group of Tyr59A and the aliphatic chain of 
Leu57A. Moreover, this benzene ring also mediates  stacking interactions with the benzene ring 
of Tyr59B. Pyridine ring of compound 4 showed hydrophobic interaction with Tyr119 residue of 
chains A and B respectively. Furthermore, the pyrrolidine ring of compound exhibiting 
hydrophobic interaction with Tyr151 and Gln61 of chain A. Dioxin ring of ligand also interacts 
hydrophobically with the tyrosine (Tyr59 and Tyr151) residues of chain B. 
Previously, it was reported that hydrophobic interaction plays an important role in accommodating 
ligands within the active site of TNF-α (He, 2005).  Compound 2 and compound 6 share a similar 






of TNF-α. Similarly, compound 5 (ZINC73690990) (dock score -6.92 kcal/mol) interacts with the 
TNF-α via hydrophobic as well as hydrogen bonding interaction. Fluorobenzene ring of ligand  
 
interacts hydrophobically by Tyr59, Gln61, Tyr119, and Tyr151 of chain A. Leu57A, Tyr119B, 
and Tyr59 of chain B also involved in hydrophobic interactions with this compound. The oxygen 
atom of ligand molecule forming a hydrogen bond with the backbone amide nitrogen of Gly121 
of chain A. Another hydrogen bonding has been observed between the isoxazole ring of ligand 
molecule with the backbone amide nitrogen of Gly121 of chain B. 
In the case of compound 6 (ZINC11915498) with dock score -6.73 kcal/mol, it stabilizes itself by 
mediating the number of hydrophobic interactions. The Chlorobenzene ring of the compound 
interacts hydrophobically with Tyr59B and Gln61B. Similarly, the Cyclohexane ring of ligand 
showed hydrophobic interaction with the aromatic ring of Tyr119A. Additionally, Tyr119 is 
making pie stacking interaction with the isoxazole ring of the ligand molecule. The oxygen atom 
in ligand molecule exhibiting a hydrogen bonding interaction with backbone amide nitrogen of 
Gly121 of chain A. From the docking analysis of lead compounds, it was revealed that all the 
compounds showed good binding pattern and interaction within the binding pocket by mediating 
several hydrogen bonding and hydrophobic interactions (Figure 10) showing their ability to inhibit 
















Figure 10. Dock poses of virtual hits: ZINC058418961, ZINC09402309, ZINC04502991, ZINC29558932, 
ZINC73690990, ZINC11915498 are shown in panel (a-f) in alphabetical order. TNF-α hotspot residues are 
represented as thick khaki sticks (chain A), thick green sticks (Chain B) and cyan color represented the ligand’s 
structure. The dash red lines show the hydrogen bonding interaction. 
 
3.8 Molecular Dynamic Simulation 
Molecular dynamics simulation is an important tool for the validation of experimentally well-
defined biological activities through finding the binding interactions between protein and its 






is its ability to analyze protein-ligand systems in aqueous solution at physiological conditions, thus 
maximizing resemblance of the computational model to real physical-chemical conditions of the  
 
environment realized in an experiment.  Also, the dynamics of the system at molecular scales can 
be investigated, the property that is impossible to obtain in all other computational approaches in 
drug design.  It is known that water and ions play a crucial role in the structure and, especially, the 
dynamics of proteins.  It is, therefore, possible that the results obtained in virtual screening and 
docking could be corrected by the presence of water and ions at room temperature.   
We have examined the structural or conformational changes in the active site of TNF-α protein 
against its respective inhibitors. MD Simulation was performed for the five complexes including 
apo-protein, reference compound, and three lead molecules. It represents the overall stability of 
each complex during the 100 nanoseconds simulation run. The stability of all the complexes was 
studied by Root mean square deviation (RMSD), Root-mean-square fluctuation (RMSF), Radius 
of gyration (Rg) and the number of hydrogen bonds. 
 
3.9 Root mean square deviation (RMSD) 
To rationalize the reliability of our sampling protocol and to determine the stability of protein 
structure during the 100 ns simulation, the RMSD curves of the backbone atoms of protein were 
calculated and compared with its initial coordinates. All the five complexes showed variable 
deviations during simulation in the backbone of TNF-α. The RMSD of all complexes was 
calculated by using the g_rms tool of Gromacs software. After the equilibration phase, the 
Simulation system of reference compound rose continuously from 0.34-0.42 nm and finally, after 






compound 1 rose continuously in the first 35ns, increasing from 0.37-0.39 nm and after 40ns 
attained stability with an average of 0.37nm during the entire simulation. In all simulation systems,  
 
compound 2 and 3 reach equilibrium early and show less fluctuation during 100ns simulation. A 
small fluctuation was observed in compound 3 between 12-33ns that was slightly increased in 
rmsd 0.37nm, then slowly decreased and stabilized at 0.36nm. In the light of above analysis, the 
simulated confirmation of all the system has small deviation from their initial conformation, and 
RMSD values of apo, reference and compound 1,2,3 were in a stable range after MD simulation 
such as 0.44 nm, 0.4 nm, 0.37 nm,0.34nm, and 0.36 nm respectively (Figure 11).  
 
Figure 11. a) The Root Mean Square Deviation (RMSD) plots all complexes over the course of 100ns simulation. 
 
3.10 Root Mean Square Fluctuation (RMSF) 
In order to determine the ligand-binding effect on the stability of protein structure RMSF analysis 






of backbone atoms was calculated by the g_rmsf tool implemented in Gromacs software. The 
RMSF of backbone atoms (N, Cα, and C) of TNF-α in each system were examined and calculated  
 
by MD trajectories. The active site residues (Leu57 A& B, Tyr59 A & B, Ser60 A & B, Glu61 
A & B, Tyr119 A & B, Leu120 A & B, Gly121-122 A & B, Tyr151 A & B) in all ligand-protein 
complexes were showing stability by maintaining the average RMSF value of 0.1 + 0.15 nm 
indicating that residues seem to be more rigid in the presence of ligands. The average fluctuation 
of all complexes was found to be 0.015nm (reference), 0.016nm (compound 1), 0.023nm 
(compound 2), and 0.016nm (compound 3) respectively.  Most of the higher fluctuations were 
observed in loop regions of chain A (residue no. 21-26, 32-40,104-112) and chain B (residue 
no.168-174, 232-236) because these loops are a most flexible part of the protein.  
 
 
Figure 12. Comparative backbone RMSF of all the complexes. The visual depicts a significant difference in the 










3.11 Radius of gyration (Rg) 
The radius of gyration measures the compactness level of protein structure and lower Rg values 
show that the structure is more compact and stable showing lower conformational entropy 
(Lobanov, Bogatyreva & Galzitskaya, 2008). We performed the Rg analysis of all complexes and 
apoprotein by using the g_rms tool implemented in Gromacs software. Figure 13 demonstrates 
the major fluctuation of apoprotein starting from 2.07A and slightly fluctuating 2.04 to 2.03 after 
6.5ns attained stability at 2.03 Å for the entire 100ns simulation. In contrast, the Rg values of the 
reference compound, compound 1, 2, 3 were showed structural stability at 2.02A, 2.01 A, 2.02 A 
and 2.0 A respectively. The values of Rg for reference, compound 2 and 3 tended to be stable and 
fluctuated constantly till 5 ns and converged throughout the simulation, but compound 1 showed 
high fluctuations till 8ns and then became stable during the entire simulation. In comparison to 
apoprotein, the TNF complex with its inhibitors showed low Rg values indicating less 







Figure 13. showing Rg of every complex throughout the 100ns simulation. 
 
3.12 Hydrogen bond Analysis 
Hydrogen bonds play a significant role in protein stability and it helps in increasing the stability 
of protein-ligand complexes (Fu, Zhao & Chen, 2018). The number of hydrogen bonds was 
determined by using the g_hbond tool in Gromacs. The predicted binding pattern of all lead 
compounds was well correlated in docking as well as in MD analysis. As TNF-α has a largely 
hydrophobic pocket, in case of reference compound no hydrogen bonding was observed and it 
resides within the TNF binding pocket by interacting hydrophobically with the hot spot residues. 
Moreover, we identified three lead compounds ZINC05848961 (Compound 1), ZINC09402309 
(Compound 2), ZINC04502991 (Compound 3), that were showing several hydrophobic as well as 
good hydrogen bonding interaction within the TNF-α binding pocket.  The compound 1 forming 
two strong hydrogen-bonding interactions with the oxygen atom of Gly121A and one with the 







Gly121A was stable after 12ns while the second hydrogen bond with this residue was not stable 
and fluctuated continuously throughout the simulation, and the third hydrogen bond with Leu120A 
was lost during the entire simulation.  
In the case of Compound 2, it forms two hydrogen bonds with amide nitrogen of Gly121 of chain 
A and a third one with the hydroxyl moiety of the Tyr151A. Among these three hydrogen bonds, 
only one with Gly121A is stable after 5ns and fluctuated substantially throughout the simulation, 
while the second hydrogen bond (Gly121A) was lost after 40ns simulation and again re-appeared 
at 90ns of simulation. The third hydrogen bond between Tyr151A and compound 2 was completely 
lost during the 100ns simulation. The compound 3 stabilizes itself by forming five hydrogen bonds 
with Ser60A, Gln61B, Tyr119A, and Leu120A and Tyr151A, but only Ser60A and Leu120 were 
stable during the later stages of molecular dynamics simulation. The hydrogen bonds between 
Gln61B, Tyr119A, Tyr151A were not stable and fluctuated continuously during the entire 
simulation. The hydrogen bonding interaction of all compounds was depicted in Figure 14. 
Moreover, all the compounds showed good hydrophobic interactions with crucial tyrosine residues 
of chain A & B (Tyr59, Tyr119, and Tyr151) and Leu57 of chain A and were well correlated with 
docking results. The detailed structural understandings and knowledge of these predicted virtual 
hits proved that it can be effective in autoimmune therapies. Moreover, in vivo or in vitro 













Figure 14. Stability interpretation of all complexes using intermolecular hydrogen bonding pattern as a function of 
time. 
3.13 Pharmacological Prediction of Selected Hits 
All the selected hits were evaluated for their physicochemical and pharmacokinetic properties 
using the Swiss ADME online server and results were shown in Figure 15 and Table 5 & 6. The 
prediction of drug-likeness was also calculated based on the Lipinski, Ghose, Veber, Egan, 
Mugguae rules and bioavailability scores. According to Lipinski rules the good absorption or 
permeation of a molecule is more likely when MW <5 g/mol, LogP <5, HBD <5 and < 10 HBA 







bonds and TPSA < 140 A2. The Ghose filter characterizes the molecules based on their 
physicochemical properties such as log P (between -0.4 and 5.6), Molar refractivity (between 30 
and 130), and a total number of atoms (between 20 and 70). Egan filter provides a prediction of 
drug absorption properties based on the membrane permeability. The Muegee model refers to some 
functional groups as pharmacophoric points (amide, amine, alcohol, sulfone, ketone sulfonamide, 
carbamate, carboxylic acid, guanidine, amidine, ester, and urea) to classify drug-like and non-
drug-like molecules. These pharmacophoric points provide significant interactions with the target 
receptor. Considering above mentioned filters, all the predicted hits are compatible with all drug-
likeness parameters and have good oral bioavailability profiles (0.55) according to Egan et al. 
(Egan, Merz, & Baldwin, 2000) as shown in Table 6 & 7. It indicated that all the compounds were 
suitable and well absorbed in the human body.  
Moreover, logP and logS values were also determined by the Swiss ADME online server. 
According to the calculated logP values, it can be concluded that all the compounds have good 
lipid solubility which will facilitate the drug interaction with the biological membranes and to be 
used for bioactivity generation. The ZINC04502991 was considered as least lipophilic due to its 
low log P-value. (iLOGP =   -1.66). The compounds water solubility was predicted via the ESOL 
method and log S values were in the range of -5.31-3.71 indicating that all compounds were 
moderately water-soluble. Furthermore, the synthetic accessibility score (SA) refers to the 
estimation of ease of synthesis of compounds and the SA score of all the compounds (3.77-2.48) 
was in the range of easy synthetic accessibility. PAINS (Pan-assay interference compounds) are 
those chemical compounds that give false-positive results in high-throughput screening and 







(Baell, Ferrins, Falk & Nikolakopoulos, 2013). In Swiss ADME evaluation, no PAINS alert was 
observed representing the specific nature of compounds. 
 
Table 5. Predicted Physiochemical properties of the selected virtual hits compounds by Swiss ADME. 





































C19H15BrN2O3 399.24 25 16 0.11 6 4 1 99.52 68.29 
ZINC09402309 C19H15BrN4O3S 459.32 28 15 0.21 6 5 0 113.14 111.71 
ZINC04502991 C14H17N3O3S2 339.43 22 11 0.36 7 5 1 86.38 125.64 
ZINC11915498 C17H19ClN2O3 334.8 23 11 0.41 5 4 1 89.04 64.36 
ZINC29558932 C20H23N3O3 353.41 26 12 0.4 5 4 1 101.66 63.69 
ZINC73690990 C18H15FN4O3S 386.4 27 18 0.22 6 7 1 100 118.38 
 
 





















































ZINC09402309 0 0 0 0 0 0.55 2.94 0 2.56 -4.06 
ZINC04502991 0 0 0 0 0 0.55 3.29 0 1.66 -3.71 
ZINC29558932 0 0 0 0 0 0.55 3.7 0 2.63 -3.82 
ZINC11915498 0 0 0 0 0 0.55 3.77 0 2.54 -4.49 
ZINC73690990 0 0 0 0 0 0.55 3.5 0 3.03 -4.83 
 
Human gastrointestinal absorption (GI), blood-brain barrier permeability and permeation of skin 








molecules (Berben et al., 2018). The boiled egg analysis of SwissADME was used to predict the 
bioavailability properties of all compounds.  
 
 
Figure 15. Boiled Egg Analysis (water partition coefficient (WlogP) vs. Topological polar surface area (TPSA) of 
selected lead compounds by SwissADME server. 
 
The results of boiled egg analysis revealed that all the predicted compounds showed high GI 
absorption indicated that they are suitable for oral administration and ZINC05848961, 
ZINC11915498, ZINC29558932 were able to cross the blood-brain barrier due to their high 
lipophilic nature. ZINC09402309 (-7.45 cm/s), ZINC29558932 (-6.45 cm/s) and ZINC04502991(-
6.24 cm/s) were predicted to have less skin permeability while ZINC11915498 have high skin 
permeability (-5.47 cm/s). P-glycoproteins (p-gp) are ATP driven efflux pumps involved in the 
transport of drugs in various organs and often responsible for drug resistance for anti-cancer drugs 







This proposed that the predicted have a lower chance of efflux out of the cell that will help in 
producing the maximal effect of the drug. 
The cytochrome P450 enzymes family plays a vital role in the biotransformation of drugs. These 
enzymes are important determinants of drug metabolism which can lead to decrease 
pharmacological effects and drug toxicities (Jana & Paliwal, 2007). The compound 
ZINC05848961, ZINC11915498, ZINC73690990 were acting as an inhibitor of all the isoforms 
of the CYP family (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4). ZINC09402309, 
ZINC04502991 is the inhibitor of all isoforms except CYP2D6, CYP3A4, CYP1A2, and 
CYP2C9). Most of the drugs are activated or inactivated by these enzymes, therefore, some 
biological assays will be needed to explore the activation and deactivation mechanism of these 
compounds by CYP isoforms (Table 7). 
 


























ZINC05848961 High Yes No Yes Yes Yes Yes Yes -5.65 
ZINC09402309 High No No Yes Yes Yes No Yes -7.56 
ZINC04502991 High No No Yes Yes Yes No No -6.28 
ZINC05848961 High Yes No No Yes No Yes Yes -6.45 
ZINC09402309 High Yes Yes Yes Yes Yes Yes Yes -5.47 
ZINC04502991 High No No Yes Yes Yes Yes Yes -5.84 
 
 
The selected hits were also analyzed for the toxicity profiles using Osiris DatawarriorV.5.0.0 
software (Sander, Freyss, von Korff & Rufener, 2015). According to the toxicity prediction (Table 







except ZINC11915498, which is highly mutagenic, tumorigenic, reproductive effect and low 
irritant. This compound can cross the BBB but did not violate the drug-likeness rules, also have 
high GIT absorption and skin permeation therefore due to high toxic properties it cannot be 
considered as TNF-inhibitor. 
 




TNF-α is a multifunctional proinflammatory cytokine responsible for various pathological 
conditions and acts as a potential drug target to combat autoimmune and inflammatory disorders. 
In this study, we employed exhaustive computational drug design protocol including ligand-based 
pharmacophore mapping, virtual screening, docking, and MD simulation to develop potent small-
molecule TNF inhibitors. In this connection, the validated pharmacophore model was used as a 
three-dimensional query in the screening of four small molecules libraries (Chembridge, 
Maybridge, NCI, and ZINC). The subsequent validation and statistical analysis suggested that the 
generated pharmacophore model has a good ability to differentiate between active and decoys  
 
Toxicity Profiles of Selected Hits 
 











ZINC09402309 None None None None 
ZINC04502991 None None None None 
ZINC29558932 None None None None 
ZINC11915498 High High High Low 







datasets. The pharmacophore screen hits were subjected to molecular docking studies to find out 
their binding modes with the target receptor. Molecular docking results suggested that the selected 
inhibitors have the potential to inactivate the TNF-α dimer by interacting with crucial residues by 
the formation of hydrogen bonds and hydrophobic interactions in a simultaneous fashion. Finally, 
six hits with diverse scaffolds were considered as lead candidates based on their highest binding 
affinity and good binding interaction with the target receptor. Moreover, in silico ADMET analysis 
suggested that all five leads possess good ADMET properties except ZINC11915498 due to its 
high predicted toxicity. Furthermore, MD simulation studies revealed that all three leads 
(ZINC05848961, ZINC09402309, ZINC04502991) showed good stability and remain in the 
binding pocket throughout the simulation. In conclusion, these leads have diverse scaffolds and 
can possibly act as starting points in further designing of potent small molecular inhibitors, but 
further experimental validation is required to prove their inhibitory activities. 
 
Acknowledgements 
The authors are grateful to the Higher Education Commission (HEC) for their Financial Support. 
 
Disclosure statement 












• Abraham, M., Murtola, T., Schulz, R., Páll, S., Smith, J., Hess, B., & Lindahl, E. (2015). 
GROMACS: High-performance molecular simulations through multi-level parallelism 
from laptops to supercomputers. SoftwareX, 1-2, 19-25. 
 
• Adegbola, S., Sahnan, K., Warusavitarne, J., Hart, A., & Tozer, P. (2018). Anti-TNF 
Therapy in Crohn’s Disease. International Journal of Molecular Sciences, 19(8), 2244. 
 
• Ajmal Shah, M., Khalil, R., Ul-Haq, Z., & Panichayupakaranant, P. (2017). α-Glucosidase 
inhibitory effect of rhinacanthins-rich extract from Rhinacanthus nasutus leaf and 
synergistic effect in combination with acarbose. Journal of Functional Foods, 36, 325-331. 
 
• Alexiou, P., Papakyriakou, A., Ntougkos, E., Papaneophytou, C., Liepouri, F., & Mettou, 
A. et al. (2014). Rationally Designed Less Toxic SPD-304 Analogs and Preliminary 
Evaluation of Their TNF Inhibitory Effects. Archiv Der Pharmazie, 347(11), 798-805.  
 
• Baell, J., Ferrins, L., Falk, H., & Nikolakopoulos, G. (2013). PAINS: Relevance to Tool 
Compound Discovery and Fragment-Based Screening. Australian Journal of 
Chemistry, 66(12), 1483.  
 
• Berendsen, H., Postma, J., van Gunsteren, W., DiNola, A., & Haak, J. (1984). Molecular 
dynamics with coupling to an external bath. The Journal of Chemical Physics, 81(8), 3684-
3690.  
 
• Berman, H. (2000). The Protein Data Bank. Nucleic Acids Research, 28(1), 235-242. 
 
• Berben, P., Bauer-Brandl, A., Brandl, M., Faller, B., Flaten, G., & Jacobsen, A. et al. 
(2018). Drug permeability profiling using cell-free permeation tools: Overview and 
applications. European Journal of Pharmaceutical Sciences, 119, 219-233.  
 
• Bender, A., & Glen, R. (2005). A Discussion of Measures of Enrichment in Virtual 
Screening:  Comparing the Information Content of Descriptors with Increasing Levels of 







• Berg, T. (2003). Modulation of Protein-Protein Interactions with Small Organic 
Molecules. Angewandte Chemie International Edition, 42(22), 2462-2481. 
 
• Bongartz, T., Matteson, E., & Orenstein, R. (2005). Tumor necrosis factor antagonists and 
infections: The small print on the price tag. Arthritis & Rheumatism, 53(5), 631-635.  
 
• Bowie, J., Luthy, R., & Eisenberg, D. (1991). A method to identify protein sequences that 
fold into a known three-dimensional structure. Science, 253(5016), 164-170.  
 
• Buchwald, P. (2010). Small-molecule protein-protein interaction inhibitors: Therapeutic 
potential in light of molecular size, chemical space, and ligand binding efficiency 
considerations. IUBMB Life, 62(10), 724-731. 
 
• Chan, F., Siegel, R., & Lenardo, M. (2000). Signaling by the TNF Receptor Superfamily 
and T Cell Homeostasis. Immunity, 13(4), 419-422. 
 
• Chan, D., Lee, H., Yang, F., Che, C., Wong, C., & Abagyan, R. et al. (2010). Structure-
Based Discovery of Natural-Product-like TNF-α Inhibitors. Angewandte Chemie, 122(16), 
2922-2926.  
 
• Cheng, J., & et al., e. (2004). Discovery and Structure-Activity Relationship of Coumarin 
Derivatives as TNF-α Inhibitors. Cheminform, 35(36). 
 
• Choi, H., Lee, Y., Park, H., & Oh, D. (2010). Discovery of the inhibitors of tumor necrosis 
factor-alpha with structure-based virtual screening. Bioorganic & Medicinal Chemistry 
Letters, 20(21), 6195-6198.   
• Clark, M., Cramer, R., & Van Opdenbosch, N. (1989). Validation of the general purpose 
tripos     5.2 force field. Journal of Computational Chemistry, 10(8), 982-1012. 
 
• Colovos, C., & Yeates, T. (1993). Verification of protein structures: Patterns of nonbonded 
atomic interactions. Protein Science, 2(9), 1511-1519. 
 
• Cortes, C., & Vapnik, V. (1995). Support-vector networks. Machine Learning, 20(3), 273-
297. 
 
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: a free web tool to evaluate 
pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small 







• Davis, J. M., & Colangelo, J. (2013). Small-molecule inhibitors of the interaction between 
TNF and TNFR. Future Medicinal Chemistry, 5(1), 69-79. 
 
• Darden, T., York, D., & Pedersen, L. (1993). Particle mesh Ewald: An N⋅log(N) method 
for Ewald sums in large systems. The Journal of Chemical Physics, 98(12), 10089-10092.  
 
• Dhuru, S., Bhedi, D., Gophane, D., Hirbhagat, K., Nadar, V., & More, D. et al. (2011). 
Novel diarylheptanoids as inhibitors of TNF-α production. Bioorganic & Medicinal 
Chemistry Letters, 21(12), 3784-3787.  
 
• Durrant, J., & McCammon, J. (2011). Molecular dynamics simulations and drug 
discovery. BMC Biology, 9(1).   
 
• Egan, W., Merz, K., & Baldwin, J. (2000). Prediction of Drug Absorption Using 
Multivariate Statistics. Journal Of Medicinal Chemistry, 43(21), 3867-3877. 
 
• Empereur-mot, C., Guillemain, H., Latouche, A., Zagury, J., Viallon, V., & Montes, M. 
(2015). Predictiveness curves in virtual screening. Journal Of Cheminformatics, 7(1).   
 
• Essmann, U., Perera, L., Berkowitz, M., Darden, T., Lee, H., & Pedersen, L. (1995). A 
smooth particle mesh Ewald method. The Journal of Chemical Physics, 103(19), 8577-
8593. 
 
• EUGENE, V., SERGEY, A. & GALA, V. 2010. ChemBridge. US private company. 
 
• Fu, Y., Zhao, J., & Chen, Z. (2018). Insights into the Molecular Mechanisms of Protein-
Ligand Interactions by Molecular Docking and Molecular Dynamics Simulation: A Case 
of Oligopeptide Binding Protein. Computational and Mathematical Methods In 
Medicine, 2018, 1-12.  
 
• Fuhrmann, J., Rurainski, A., Lenhof, H., & Neumann, D. (2010). A new Lamarckian 
genetic algorithm for flexible ligand-receptor docking. Journal of Computational 
Chemistry, NA-NA. 
 
• Fujita, M. (2002). Design, synthesis, and bioactivities of novel diarylthiophenes: inhibitors 
of tumor necrosis factor-α (TNF-α) production. Bioorganic & Medicinal Chemistry, 
10(10), 3113-3122.   
 
• Gao, Q., Yang, L., & Zhu, Y. (2010). Pharmacophore Based Drug Design Approach as a 







• Gasteiger, J. (2005). Chemoinformatics: a new field with a long tradition. Analytical and 
Bioanalytical Chemistry, 384(1), pp.57-64.  
 
• Ghose, A., Viswanadhan, V., & Wendoloski, J. (1999). A Knowledge-Based Approach in 
Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A 
Qualitative and Quantitative Characterization of Known Drug Databases. Journal of 
Combinatorial Chemistry, 1(1), 55-68. 
 
• GRANT, J., GALLARDO, M., & PICKUP, B. (1996). A fast method of molecular shape 
comparison: A simple application of a Gaussian description of molecular shape. Journal 
of Computational Chemistry, 17(14), 1653-1666.  
 
• Guirado, A., López Sánchez, J., Ruiz-Alcaraz, A., García-Peñarrubia, P., Bautista, D., & 
Gálvez, J. (2013). First synthesis and biological evaluation of 4-amino-2-aryl-6,9-
dichlorobenzo[g]pteridines as inhibitors of TNF-α and IL-6. European Journal of 
Medicinal Chemistry, 66, 269-275.  
 
• Hanumanthappa, P., K. Teli, M., & G. Krishnamurthy, R. (2012). Generation of 
Pharmacophore and Atom Based 3D-QSAR Model of Novel Isoquinolin-1-one and 
Quinazolin-4-one-type Inhibitors of TNFα. Medicinal Chemistry, 8(3), 436-451.  
 
• He, M. (2005). Small-Molecule Inhibition of TNF-. Science, 310(5750), 1022-1025. 
 
• Hess, B., Bekker, H., Berendsen, H., & Fraaije, J. (1997). LINCS: A linear constraint solver 
for molecular simulations. Journal of Computational Chemistry, 18(12), 1463-1472.  
 
• Hochberg, M., Lebwohl, M., Plevy, S., Hobbs, K., & Yocum, D. (2005). The Benefit/Risk 
Profile of TNF-Blocking Agents: Findings of a Consensus Panel. Seminars In Arthritis And 
Rheumatism, 34(6), 819-836. 
 
• Idriss, H., & Naismith, J. (2000). TNF? and the TNF receptor superfamily: Structure-
function relationship(s). Microscopy Research and Technique, 50(3), 184-195.  
 
• Irwin, J. J. & Shoichet, B. K. 2005. ZINC a free database of commercially available 








• Jacobi, A., Mahler, V., Schuler, G., & Hertl, M. (2006). Treatment of inflammatory 
dermatoses by tumor necrosis factor antagonists. Journal of The European Academy Of 
Dermatology And Venereology, 20(10), 1171-1187.  
 
• Jang, J., Yoon, H., Yoon, J., Kim, H., Lee, S., & Kim, K. et al. (2009). Crystal Structure of 
the TNF-α-Inducing Protein (Tipα) from Helicobacter pylori: Insights into Its DNA-
Binding Activity. Journal of Molecular Biology, 392(1), 191-197. 
 
• Jana, S., & Paliwal, J. (2007). Molecular Mechanisms of Cytochrome P450 Induction: 
Potential for Drug-Drug Interactions. Current Protein & Peptide Science, 8(6), 619-628.  
 
• Kang, T., Mao, Z., Ng, C., Wang, M., Wang, W., & Wang, C. et al. (2016). Identification 
of an Iridium(III)-Based Inhibitor of Tumor Necrosis Factor-α. Journal of Medicinal 
Chemistry, 59(8), 4026-4031. 
 
• Kim, Y., Hong, Y., Joo, Y., Woo, B., Kim, S., & Koh, H. et al. (2014). Synthesis and 
structure-activity relationship of cyclopentenone oximes as novel inhibitors of the 
production of tumor necrosis factor-α. Bioorganic & Medicinal Chemistry Letters, 24(13), 
2807-2810.  
 
• Laskowski, R., MacArthur, M., Moss, D., & Thornton, J. (1993). PROCHECK: a program 
to check the stereochemical quality of protein structures. Journal of Applied 
Crystallography, 26(2), 283-291. 
 
• Laufersweiler, M., & et al., e. (2004). The Development of Novel Inhibitors of Tumor 
Necrosis Factor-α (TNF-α) Production Based on Substituted [5,5]-Bicyclic Pyrazolones. 
Cheminform, 35(49).  
 
 
• Leung, C., Zhong, H., Yang, H., Cheng, Z., Chan, D., & Ma, V. et al. (2012). A Metal-
based Inhibitor of Tumor Necrosis Factor-α. Angewandte Chemie International 
Edition, 51(36), 9010-9014.  
 
• Leung, C., Chan, D., Kwan, M., Cheng, Z., Wong, C., & Zhu, G. et al. (2011). Structure-
Based Repurposing of FDA-Approved Drugs as TNF-α Inhibitors. Chemmedchem, 6(5), 
765-768.  
 
• Liang, S., Dai, J., Hou, S., Su, L., Zhang, D., & Guo, H. et al. (2013). Structural Basis for 
Treating Tumor Necrosis Factor α (TNF-α)-associated Diseases with the Therapeutic 







• Li, Z., Wan, H., Shi, Y. and Ouyang, P. (2004). Personal Experience with Four Kinds of 
Chemical Structure Drawing Software: Review on ChemDraw, ChemWindow, ISIS/Draw, 
and ChemSketch. Journal of Chemical Information and Computer Sciences, 44(5), 
pp.1886-1890.  
 
• Lin, J., & Yamazaki, M. (2003). Role of P-Glycoprotein in Pharmacokinetics. Clinical 
Pharmacokinetics, 42(1), 59-98.  
 
• Lis, K., Kuzawińska, O., & Bałkowiec-Iskra, E. (2014). State of the art paper Tumor 
necrosis factor inhibitors – state of knowledge. Archives of Medical Science, 6, 1175-1185.   
 
• Lipinski, C., Lombardo, F., Dominy, B., & Feeney, P. (2001). Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings 1PII of original article: S0169-409X(96)00423-1. The article was 
originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1. Advanced 
Drug Delivery Reviews, 46(1-3), 3-26. 
 
• Lipinski, C. (2004). Lead- and drug-like compounds: the rule-of-five revolution. Drug 
Discovery Today: Technologies, 1(4), 337-341. 
 
• Lobanov, M., Bogatyreva, N., & Galzitskaya, O. (2008). The radius of gyration as an 
indicator of protein structure compactness. Molecular Biology, 42(4), 623-628.   
 
• Louis S. (2007). Sybyl, version 7.3; software for molecular modeling package. 
 
• Lüthy, R., Bowie, J., & Eisenberg, D. (1992). Assessment of protein models with three-
dimensional profiles. Nature, 356(6364), 83-85.  
 
• Ma, L., Gong, H., Zhu, H., Ji, Q., Su, P., & Liu, P. et al. (2014). A Novel Small-molecule 
Tumor Necrosis Factor α Inhibitor Attenuates Inflammation in a Hepatitis Mouse 
Model. Journal Of Biological Chemistry, 289(18), 12457-12466.  
 
• Malde, A., Zuo, L., Breeze, M., Stroet, M., Poger, D., & Nair, P. et al. (2011). An 
Automated Force Field Topology Builder (ATB) and Repository: Version 1.0. Journal of 
Chemical Theory And Computation, 7(12), 4026-4037.  
 
• Mancini, F., Toro, C., Mabilia, M., Giannangeli, M., Pinza, M., & Milanese, C. (1999). 






analogs of suramin§§Abbreviations: TNF-α, tumor necrosis factor-α; and MC/EM, 
MonteCarlo/energy minimization. Biochemical Pharmacology, 58(5), 851-859.  
 
• Mark, P., & Nilsson, L. (2001). Structure and Dynamics of the TIP3P, SPC, and SPC/E 
Water Models at 298 K. The Journal of Physical Chemistry A, 105(43), 9954-9960.  
 
• Maxwell, L., Zochling, J., Boonen, A., Singh, J., Veras, M., & Tanjong Ghogomu, E. et al. 
(2015). TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Of 
Systematic Reviews, Art. No.: CD005468.(4). 
 
• McInnes, I., Buckley, C., & Isaacs, J. (2015). Cytokines in rheumatoid arthritis — shaping 
the immunological landscape. Nature Reviews Rheumatology, 12(1), 63-68.  
• Mesaik, M., Jabeen, A., Halim, S., Begum, A., Khalid, A., & Asif, M. et al. (2012). In 
Silico and In Vitro Immunomodulatory Studies on Compounds of Lindelofia 
stylosa. Chemical Biology & Drug Design, 79(3), 290-299. 
 
• Monaco, C., Nanchahal, J., Taylor, P., & Feldmann, M. (2014). Anti-TNF therapy: past, 
present, and future. International Immunology, 27(1), 55-62.  
 
• Morris, G., Huey, R., Lindstrom, W., Sanner, M., Belew, R., Goodsell, D. and Olson, A. 
(2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor 
flexibility. Journal of Computational Chemistry, 30(16), pp.2785-2791. 
 
• Mouchlis, V., Melagraki, G., Mavromoustakos, T., Kollias, G. and Afantitis, A. (2012). 
Molecular Modeling on Pyrimidine-Urea Inhibitors of TNF-α Production: An Integrated 
Approach Using a Combination of Molecular Docking, Classification Techniques, and 3D-
QSAR CoMSIA. Journal of Chemical Information and Modeling, 52(3), pp.711-723. 
 
 
• Mouhsine, H., Guillemain, H., Moreau, G., Fourati, N., Zerrouki, C., & Baron, B. et al. 
(2017). Identification of an in vivo orally active dual-binding protein-protein interaction 
inhibitor targeting TNFα through combined in silico/in vitro/in vivo screening. Scientific 
Reports, 7(1).  
 
• Muegge, I. (2003). Selection Criteria for Drug-Like Compounds. Cheminform, 34(29).  
 
• Mysinger, M., Carchia, M., Irwin, J., & Shoichet, B. (2012). Directory of Useful Decoys 
Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking. Journal of 








• Palladino, M., Bahjat, F., Theodorakis, E., & Moldawer, L. (2003). Anti-TNF-α therapies: 
the next generation. Nature Reviews Drug Discovery, 2(9), 736-746. 
 
• Papadakis, K., & Targan, S. (2000). Tumor necrosis factor: Biology and therapeutic 
inhibitors. Gastroenterology, 119(4), 1148-1157.  
 
• Pérez, A., Marchán, I., Svozil, D., Sponer, J., Cheatham, T., Laughton, C. and Orozco, M. 
(2007). Refinement of the AMBER Force Field for Nucleic Acids: Improving the 
Description of α/γ Conformers. Biophysical Journal, 92(11), pp.3817-3829. 
 
• Ramachandran, G., Ramakrishnan, C., & Sasisekharan, V. (1963). Stereochemistry of 
polypeptide chain configurations. Journal of Molecular Biology, 7(1), 95-99.   
 
• Sabat, M., & et al., e. (2006). The Development of Novel C-2, C-8, and N-9 Trisubstituted 
Purines as Inhibitors of TNF-α Production. Cheminform, 37(51).  
 
• Sander, T., Freyss, J., von Korff, M., & Rufener, C. (2015). DataWarrior: An Open-Source 
Program for Chemistry Aware Data Visualization and Analysis. Journal of Chemical 
Information and Modeling, 55(2), 460-473. 
 
• Scott, W., Hünenberger, P., Tironi, I., Mark, A., Billeter, S., & Fennen, J. et al. (1999). The 
GROMOS Biomolecular Simulation Program Package. The Journal of Physical Chemistry 
A, 103(19), 3596-3607.  
 
• SCRGUIDE 2004. The Maybridge Screening Collection- Maybridge... Bringing Life to 
Drug Discovery. Fisher Scientific. 
 
• Sedger, L., & McDermott, M. (2014). TNF and TNF-receptors: From mediators of cell 
death and inflammation to therapeutic giants – past, present, and future. Cytokine & 
Growth Factor Reviews, 25(4), 453-472.   
 
• Sfikakis, P., & Tsokos, G. (2011). Towards the next generation of anti-TNF drugs. Clinical 
Immunology, 141(3), 231-235.  
 
• Shah, M., Arfan, M., Amin, H., Hussain, Z., Qadir, M., & Iqbal Choudhary, M. et al. 
(2012). Synthesis of new bergenin derivatives as potent inhibitors of inflammatory 








• Singh, U., & Kollman, P. (1984). An approach to computing electrostatic charges for 
molecules. Journal of Computational Chemistry, 5(2), 129-145.   
 
• Stinson, S. F., Alley, M. C., Kopp, W. C., Fiebig, H. H., Mullendore, L. A., Pittman, A. F., 
Kenney, S., Keller, J. & Boyd, M. R. 1992. Morphological and immunocytochemical 
characteristics of human tumor cell lines for use in a disease-oriented anticancer drug 
screen. Anticancer Research, 12, 1035-1053. 
 
• Sticherling, M. (2016). Psoriasis and autoimmunity. Autoimmunity Reviews, 15(12), 1167-
1170.   
• Tang, P., Hung, M., & Klostergaard, J. (1996). Human pro-Tumor Necrosis Factor Is a 
Homotrimer. Biochemistry, 35(25), 8216-8225.  
 
• Triballeau, N., Acher, F., Brabet, I., Pin, J., & Bertrand, H. (2005). Virtual Screening 
Workflow Development Guided by the “Receiver Operating Characteristic” Curve 
Approach. Application to High-Throughput Docking on Metabotropic Glutamate Receptor 
Subtype 4. Journal of Medicinal Chemistry, 48(7), 2534-2547.   
 
• Truchon, J., & Bayly, C. (2007). Evaluating Virtual Screening Methods:  Good and Bad 
Metrics for the “Early Recognition” Problem. Journal of Chemical Information And 
Modeling, 47(2), 488-508.  
 
• Version, O. 2006. 2.1, OpenEye Scientific Software. 2.1 ed.  
 
• Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, et al. (2002) Molecular 
properties that influence the oral bioavailability of drug candidates. J Med Chem 45: 2615-
2623. 
 
• Vilar, S., Cozza, G., & Moro, S. (2008). Medicinal Chemistry and the Molecular Operating 
Environment (MOE): Application of QSAR and Molecular Docking to Drug 
Discovery. Current Topics in Medicinal Chemistry, 8(18), 1555-1572  
 
• Wajant, H., Pfizenmaier, K., & Scheurich, P. (2003). Tumor necrosis factor signaling. Cell 
Death & Differentiation, 10(1), 45-65.  
 
• Willett, P., Barnard, J., & Downs, G. (1998). Chemical Similarity Searching. Journal of 
Chemical Information and Computer Sciences, 38(6), 983-996. 
 
• Wolber, G., & Langer, T. (2005). LigandScout: 3-D Pharmacophores Derived from 







• Zaka, M., Sehgal, S. A., Shafique, S., & Abbasi, B. H. (2017). Comparative in silico 
analyses of Cannabis sativa, Prunella vulgaris and Withania somnifera compounds 
elucidating the medicinal properties against rheumatoid arthritis. J Mol Graph Model, 74, 
296-304. 
 
 
 
 
 
 
 
 
 
